IGF-1 DES sits in an unapproved, research-only position across nearly every regulatory system that touches it. No national drug regulator has cleared it for human use, it does not meet the statutory definition of a dietary supplement, and it is banned in sport at all times, so the honest bottom line is that nothing about its current status makes it a lawful human therapeutic. The exposure it carries lives in food-and-drug law rather than drug-scheduling law, a distinction that shapes who is at risk and how.
IGF-1 DES holds no approval from any national drug regulator, does not qualify as a dietary supplement, and is prohibited in sport at all times, leaving it an unapproved new drug under food-and-drug law rather than a lawful human therapeutic.
No approved drug product containing IGF-1 DES exists anywhere. The molecule removes the first three N-terminal amino acids of insulin-like growth factor 1, and no version of it has been reviewed by the FDA, the European Medicines Agency, Australia's Therapeutic Goods Administration, or any comparable authority for treating a disease. Much of the mistaken sense of legitimacy traces to confusion with mecasermin, a full-length recombinant IGF-1 that does carry genuine FDA approval.
| Criterion | IGF-1 DES | Mecasermin (Increlex) |
|---|---|---|
| Regulatory status | Unapproved anywhere | FDA-approved for severe primary IGF-1 deficiency |
| Clinical trials | None completed | Completed controlled trials |
| Labeling | Research-use-only disclaimer only | Prescribing label with dosing and safety monitoring |
| Access | Research-chemical channel | Prescription-dispensed |
IGF-1 DES has never been reviewed or cleared by the FDA or any comparable regulator for any human indication, unlike mecasermin, the full-length recombinant IGF-1 approved for severe primary IGF-1 deficiency.
IGF-1 DES cannot be lawfully sold as a dietary supplement, and the reason is structural rather than a matter of paperwork. The Dietary Supplement Health and Education Act requires a dietary ingredient intended for ingestion, and a synthetic injectable peptide hormone analog fails on both counts. Any product promising IGF-1 effects under a supplement label is treated instead as an unapproved and misbranded drug.
IGF-1 DES fails both statutory tests for a dietary supplement, a recognized dietary ingredient and intended ingestion, so marketing it as one renders it an unapproved, misbranded drug subject to FDA enforcement.
The phrase "research use only, not for human consumption" on IGF-1 DES vials is a liability and marketing device, not a legal classification that legitimizes the sale. Legitimate research-use-only reagents supply laboratories with materials never validated for therapeutic use, and gray-market vendors borrow the same language hoping it shifts responsibility onto the buyer. What actually governs is intended use, which the FDA infers from the full commercial context rather than the words printed on the vial.
The "research use only" disclaimer carries no legal weight because the FDA judges a product by its intended use, inferred from dosing, vial sizing, customer base, and promotional claims, and can treat the vial as an unapproved, misbranded drug regardless of the label.
IGF-1 DES is prohibited in sport at all times. The World Anti-Doping Agency lists peptide hormones, growth factors, and mimetics under its S2 category, and IGF-1 together with its analogs falls inside that growth-factor language. Because it is a non-specified substance in that class, the ban holds both in and out of competition, closing off off-season use as well.
IGF-1 DES is banned both in and out of competition under WADA's S2 peptide-hormone and growth-factor category, and a first intentional violation can carry up to four years of ineligibility plus disqualification of results.
The legal footing of IGF-1 DES shifts noticeably from one country to the next, so a single global rule does not exist. The United States leaves it in a gray unapproved-drug zone, while Australia and the United Kingdom reach it through stricter medicines and poisons controls. Across most borders, customs and postal inspection routinely intercept vials of research peptides regardless of the local classification.
| Jurisdiction | Legal treatment |
|---|---|
| United States | Unapproved new drug, not scheduled; moves under research-chemical cover |
| European Union | Handled as an unlicensed medicine under national medicines law |
| Australia | Prescription-only or prohibited-import under the Poisons Standard |
| United Kingdom | Unlicensed medicine; supplying it is an offense under the Human Medicines Regulations |
The legal status of IGF-1 DES ranges from the United States' gray unapproved-drug zone to prescription-only or prohibited-import controls in Australia and unlicensed-medicine offenses in the United Kingdom, so legality turns on the specific national framework rather than any single global rule.
The heaviest legal exposure lands on sellers, though neither side is clear of risk. Introducing an unapproved new drug into interstate commerce and misbranding a drug are prohibited acts that can support injunctions, seizures, monetary penalties, and criminal prosecution. A research-only disclaimer does not immunize a vendor whose product is really destined for human injection, because intended use is judged from the full commercial context.
Sellers of IGF-1 DES face civil injunctions, seizures, monetary penalties, and criminal prosecution under the Federal Food, Drug, and Cosmetic Act, while buyers face lighter exposure through customs seizure and, in stricter jurisdictions, civil or criminal penalties.
In the United States, IGF-1 DES is not a scheduled controlled substance, though that offers no legal cover for selling it. The Controlled Substances Act schedules drugs by their potential for abuse and dependence, a framework built around narcotics, stimulants, depressants, and anabolic steroids, and peptide growth factors do not sit on those schedules. The exposure lives instead in food-and-drug law, where a substance can be entirely illegal to sell for human use without ever being scheduled.
| Dimension | Controlled Substances Act | Food, Drug, and Cosmetic Act |
|---|---|---|
| Basis for control | Abuse and dependence potential | Approval, labeling, and intended use |
| IGF-1 DES status | Unscheduled | Unapproved new drug, unlawful to market for human use |
| Enforcing agency | Drug Enforcement Administration | Food and Drug Administration |
Under United States law IGF-1 DES is unscheduled because the Controlled Substances Act targets abuse potential, yet it remains an unapproved new drug that is unlawful to market for human use under the Food, Drug, and Cosmetic Act.
Educational use only. This article describes what the published scientific and clinical literature reports about IGF-1 DES. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
